Tag Archives: FDA

Making the Most of Social Media (Within FDA’s New Guidelines)

By Ken Ribotsky. Pharmaceutical companies have begun using social media for business needs and promotion, yet have been hesitant to become too engaged since the FDA’s stance on social media activity remained unclear. But now that we know the FDA’s specific guidelines for pharma companies’ actions online, it’s time for brands to consider diving into […]
Posted in compliance, E-Media, FDA, Guest Blog, Op-Ed, Regulatory, social media | Also tagged | 1 Comment

New Social Media Guidelines: What FDA Says, and What It Means

By Simon Beins is Associate Director, Strategy, Heartbeat Ideas & Heartbeat West. Earlier this year, FDA promised three sets of guidelines to clarify using social media for pharma marketing. Last week it delivered two of them The first, Internet/Social Media Platforms with Character Space Limitation—Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices, […]
Posted in E-Media, FDA, Guest Blog, multimedia, Regulatory, social media | Also tagged , , , | Leave a comment

US Regulators and Industry Bodies Push Forward with Global Expansion

At the annual meeting of the Food and Drug Law Institute (FDLI) this year, FDA commissioner Margaret Hamburg concluded her keynote address by describing a “dramatically changing global marketplace” and its “huge implications” for FDA’s ability to ensure the safety and quality of products manufactured elsewhere. In addition to conducting more inspections and oversight of […]
Posted in Emerging Markets, Europe, FDA, Global, Regulatory | Also tagged , , , , , | Leave a comment

Suffer Little Children? To Medicate or Not to Medicate Toddlers

When Audre McDonald accepted her sixth Tony Award (theater’s version of the Academy Awards) this month in New York City, and broadcast live on national television, she thanked her parents “for their unwillingness to put her on stimulant medication, which she believed led to her stunning success in musical theater.” In the aftermath, her comments […]
Posted in FDA, Global, healthcare | Also tagged , , , , | Leave a comment

Margaret Hamburg Addresses Biopharma’s Pressing Issues

Speaking at the 2014 New York BIO conference, FDA Commissioner, Dr. Margaret Hamburg, addressed the pressing issues affecting the biopharmaceutical industry and the FDA. Applied Clinical Trials’ Moe Alsumidaie relays Dr Hamburg’s the highlights of Dr. Hamburg’s presentation below.
Posted in FDA, R&D, Regulatory | Also tagged , , , , | 1 Comment
  • Categories

  • Meta